Annual Net Income
-$4.51 M
+$22.24 M+83.15%
31 December 2023
Summary:
Sunshine Biopharma annual net profit is currently -$4.51 million, with the most recent change of +$22.24 million (+83.15%) on 31 December 2023. During the last 3 years, it has fallen by -$1.72 million (-61.85%). SBFMW annual net income is now -34239.61% below its all-time high of -$13.12 thousand, reached on 31 July 2007.SBFMW Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Net Income
-$1.20 M
-$703.50 K-142.32%
30 September 2024
Summary:
Sunshine Biopharma quarterly net profit is currently -$1.20 million, with the most recent change of -$703.50 thousand (-142.32%) on 30 September 2024. Over the past year, it has dropped by -$546.32 thousand (-83.86%). SBFMW quarterly net income is now -172.57% below its all-time high of $1.65 million, reached on 31 December 2021.SBFMW Quarterly Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM Net Income
-$4.23 M
-$546.32 K-14.85%
30 September 2024
Summary:
Sunshine Biopharma TTM net profit is currently -$4.23 million, with the most recent change of -$546.32 thousand (-14.85%) on 30 September 2024. Over the past year, it has increased by +$22.54 million (+84.21%). SBFMW TTM net income is now -495.09% below its all-time high of $1.07 million, reached on 30 June 2011.SBFMW TTM Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SBFMW Net Income Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +83.2% | -83.9% | +84.2% |
| 3 y3 years | -61.9% | +84.1% | +78.8% |
| 5 y5 years | -109.0% | -242.0% | -163.7% |
SBFMW Net Income High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -61.9% | +83.2% | -172.6% | +94.9% | -167.2% | +84.7% |
| 5 y | 5 years | -171.4% | +83.2% | -172.6% | +94.9% | -185.7% | +84.7% |
| alltime | all time | <-9999.0% | +83.2% | -172.6% | +94.9% | -495.1% | +84.7% |
Sunshine Biopharma Net Income History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$1.20 M(+142.3%) | -$4.23 M(+14.8%) |
| June 2024 | - | -$494.30 K(-61.5%) | -$3.68 M(-10.0%) |
| Mar 2024 | - | -$1.28 M(+2.7%) | -$4.09 M(-9.3%) |
| Dec 2023 | -$4.51 M(-83.2%) | -$1.25 M(+91.9%) | -$4.51 M(-83.2%) |
| Sept 2023 | - | -$651.48 K(-27.8%) | -$26.77 M(-2.9%) |
| June 2023 | - | -$902.11 K(-47.0%) | -$27.57 M(+1.3%) |
| Mar 2023 | - | -$1.70 M(-92.8%) | -$27.21 M(+1.7%) |
| Dec 2022 | -$26.74 M(+115.0%) | -$23.51 M(+1513.7%) | -$26.74 M(+1590.9%) |
| Sept 2022 | - | -$1.46 M(+170.4%) | -$1.58 M(-79.4%) |
| June 2022 | - | -$538.87 K(-56.4%) | -$7.66 M(-37.7%) |
| Mar 2022 | - | -$1.24 M(-174.9%) | -$12.30 M(-28.7%) |
| Dec 2021 | -$12.44 M(+346.7%) | $1.65 M(-121.9%) | -$17.24 M(-13.7%) |
| Sept 2021 | - | -$7.54 M(+45.6%) | -$19.98 M(+52.0%) |
| June 2021 | - | -$5.17 M(-16.3%) | -$13.14 M(+52.7%) |
| Mar 2021 | - | -$6.19 M(+470.7%) | -$8.61 M(+242.2%) |
| Dec 2020 | -$2.78 M(+67.7%) | -$1.08 M(+55.1%) | -$2.51 M(+37.6%) |
| Sept 2020 | - | -$698.60 K(+9.4%) | -$1.83 M(+23.5%) |
| June 2020 | - | -$638.31 K(+577.2%) | -$1.48 M(-4.7%) |
| Mar 2020 | - | -$94.26 K(-76.2%) | -$1.55 M(-6.5%) |
| Dec 2019 | -$1.66 M(-23.0%) | -$396.62 K(+13.2%) | -$1.66 M(+3.6%) |
| Sept 2019 | - | -$350.24 K(-50.7%) | -$1.60 M(-25.8%) |
| June 2019 | - | -$710.89 K(+251.0%) | -$2.16 M(+3.2%) |
| Mar 2019 | - | -$202.54 K(-40.2%) | -$2.09 M(-2.9%) |
| Dec 2018 | -$2.16 M(+107.3%) | -$338.65 K(-62.7%) | -$2.16 M(+6.3%) |
| Sept 2018 | - | -$907.56 K(+40.9%) | -$2.03 M(+59.9%) |
| June 2018 | - | -$644.31 K(+142.6%) | -$1.27 M(+14.3%) |
| Mar 2018 | - | -$265.64 K(+25.6%) | -$1.11 M(+6.7%) |
| Dec 2017 | -$1.04 M(-70.3%) | -$211.48 K(+43.3%) | -$1.04 M(-46.7%) |
| Sept 2017 | - | -$147.61 K(-69.6%) | -$1.95 M(-42.4%) |
| June 2017 | - | -$485.44 K(+148.1%) | -$3.39 M(+0.1%) |
| Mar 2017 | - | -$195.70 K(-82.6%) | -$3.39 M(-3.1%) |
| Dec 2016 | -$3.50 M | -$1.12 M(-29.1%) | -$3.50 M(+15.8%) |
| Sept 2016 | - | -$1.59 M(+229.4%) | -$3.02 M(+84.5%) |
| June 2016 | - | -$481.31 K(+57.7%) | -$1.64 M(-2.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2016 | - | -$305.29 K(-52.9%) | -$1.67 M(+0.7%) |
| Dec 2015 | -$1.65 M(-14.5%) | -$647.68 K(+219.3%) | -$1.66 M(+23.3%) |
| Sept 2015 | - | -$202.81 K(-60.8%) | -$1.35 M(-5.5%) |
| June 2015 | - | -$517.51 K(+75.8%) | -$1.43 M(-17.4%) |
| Mar 2015 | - | -$294.37 K(-11.8%) | -$1.73 M(-10.7%) |
| Dec 2014 | -$1.93 M(-22.4%) | -$333.72 K(+18.8%) | -$1.93 M(-15.4%) |
| Sept 2014 | - | -$280.85 K(-65.7%) | -$2.29 M(+4.7%) |
| June 2014 | - | -$818.39 K(+63.3%) | -$2.18 M(+43.8%) |
| Mar 2014 | - | -$501.25 K(-26.9%) | -$1.52 M(-39.1%) |
| Dec 2013 | -$2.49 M(+251.9%) | -$685.78 K(+285.1%) | -$2.49 M(+24.9%) |
| Sept 2013 | - | -$178.06 K(+16.4%) | -$2.00 M(-9.1%) |
| June 2013 | - | -$152.97 K(-89.6%) | -$2.20 M(+2.3%) |
| Mar 2013 | - | -$1.48 M(+682.6%) | -$2.15 M(+203.1%) |
| Dec 2012 | -$707.95 K(+27.3%) | -$188.76 K(-49.9%) | -$707.95 K(-20.6%) |
| Sept 2012 | - | -$376.78 K(+265.6%) | -$891.25 K(+41.3%) |
| June 2012 | - | -$103.07 K(+162.0%) | -$630.90 K(+15.9%) |
| Mar 2012 | - | -$39.34 K(-89.4%) | -$544.33 K(-1.8%) |
| Dec 2011 | -$556.20 K(+3.5%) | -$372.06 K(+219.5%) | -$554.20 K(-0.9%) |
| Sept 2011 | - | -$116.44 K(+606.1%) | -$559.09 K(-152.3%) |
| June 2011 | - | -$16.49 K(-66.5%) | $1.07 M(-313.1%) |
| Mar 2011 | - | -$49.22 K(-86.9%) | -$501.95 K(-6.6%) |
| Dec 2010 | -$537.38 K(+1627.6%) | -$376.95 K(-124.9%) | -$537.38 K(+235.0%) |
| Sept 2010 | - | $1.51 M(-195.2%) | -$160.44 K(-94.3%) |
| June 2010 | - | -$1.59 M(+1776.1%) | -$2.81 M(+128.8%) |
| Mar 2010 | - | -$84.65 K(-92.5%) | -$1.23 M(+6.5%) |
| Oct 2009 | - | -$1.13 M(>+9900.0%) | -$1.15 M(+4503.3%) |
| July 2009 | - | -$8766.00(+49.1%) | -$25.02 K(+14.3%) |
| Apr 2009 | - | -$5879.00(+55.0%) | -$21.88 K(-28.1%) |
| Jan 2009 | - | -$3793.00(-42.3%) | -$30.42 K(+5.3%) |
| Oct 2008 | - | -$6578.00(+16.8%) | -$28.89 K(-7.1%) |
| July 2008 | -$31.11 K(+137.0%) | -$5631.00(-61.0%) | -$31.10 K(+22.1%) |
| Apr 2008 | - | -$14.42 K(+536.6%) | -$25.47 K(+130.5%) |
| Jan 2008 | - | -$2265.00(-74.2%) | -$11.05 K(+25.8%) |
| Oct 2007 | - | -$8788.00 | -$8788.00 |
| July 2007 | -$13.12 K | - | - |
FAQ
- What is Sunshine Biopharma annual net profit?
- What is the all time high annual net income for Sunshine Biopharma?
- What is Sunshine Biopharma annual net income year-on-year change?
- What is Sunshine Biopharma quarterly net profit?
- What is the all time high quarterly net income for Sunshine Biopharma?
- What is Sunshine Biopharma quarterly net income year-on-year change?
- What is Sunshine Biopharma TTM net profit?
- What is the all time high TTM net income for Sunshine Biopharma?
- What is Sunshine Biopharma TTM net income year-on-year change?
What is Sunshine Biopharma annual net profit?
The current annual net income of SBFMW is -$4.51 M
What is the all time high annual net income for Sunshine Biopharma?
Sunshine Biopharma all-time high annual net profit is -$13.12 K
What is Sunshine Biopharma annual net income year-on-year change?
Over the past year, SBFMW annual net profit has changed by +$22.24 M (+83.15%)
What is Sunshine Biopharma quarterly net profit?
The current quarterly net income of SBFMW is -$1.20 M
What is the all time high quarterly net income for Sunshine Biopharma?
Sunshine Biopharma all-time high quarterly net profit is $1.65 M
What is Sunshine Biopharma quarterly net income year-on-year change?
Over the past year, SBFMW quarterly net profit has changed by -$546.32 K (-83.86%)
What is Sunshine Biopharma TTM net profit?
The current TTM net income of SBFMW is -$4.23 M
What is the all time high TTM net income for Sunshine Biopharma?
Sunshine Biopharma all-time high TTM net profit is $1.07 M
What is Sunshine Biopharma TTM net income year-on-year change?
Over the past year, SBFMW TTM net profit has changed by +$22.54 M (+84.21%)